Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of IAG933 in advanced mesothelioma and other solid tumors
NL-OMON59034Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IAG933 in mesothelioma and Nonhematologic neoplasms, sponsored by Novartis. Primary endpoint: Primary endpoint(s). Started Mar 2023; status: active, not recruiting.
02
Drugs
IAG933
03
Conditions
mesotheliomaNonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON59034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59034.